Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma

Fumiyuki Uematsu,1,3 Masakazu Takahashi,1 Midori Yoshida,1 Maki Igarashi1-2 and Dai Nakae1

1Department of Pathology, Sasaki Institute, Sasaki Foundation, 2-2 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062; and 2Laboratory of Protection of Body Function, Department of Food and Nutritional Science, Graduate School of Agriculture, 1-1-1 Sakuragaoka, Setagaya-ku, Tokyo 156-0054, Japan

(Received January 26, 2006/Revised March 16, 2006/Accepted March 20, 2006/Online publication May 1, 2006)

Neutral endopeptidase 24.11 (NEP), a cell-surface enzyme expressed by epithelial cells that cleaves and inactivates biologically active small peptides, is downregulated in various cancers. NEP is encoded by a gene that contains a CpG island in the promoter region, whose hypermethylation appears related to decreased expression. Altered expression of NEP has also been reported in human hepatocellular carcinoma (HCC), suggesting its possible role in hepatocarcinogenesis. To elucidate the status of NEP in HCC, methylation in the promoter region of the gene that encodes NEP in male Fischer 344 rats with HCC, induced by a choline-deficient, L-amino acid-defined diet, was investigated by methylation-specific polymerase chain reaction, combined bisulfite restriction analysis, reverse transcription–polymerase chain reaction, reverse transcription–polymerase chain reaction, and bisulfite genomic sequencing. These analyses together showed the promoter to be frequently methylated in HCC in contrast to its unmethylated status in normal liver, the degree of methylation being inversely related to the level of mRNA expression evaluated by reverse transcription–polymerase chain reaction (P = 0.031). In two rat liver cell lines, RLC-16 and RLC-27, the promoter was heavily methylated and NEP mRNA expression was negative. However, administration of 5-aza-2′-deoxycytidine caused NEP expression, suggesting that methylation of CpG is a factor regulating transcriptional expression. Together with the data from microarray analyses performed previously using the same animal model, the current results suggest that reduced expression of NEP or other ectopeptidases could impact on molecules involved in signal-transducing systems, including G-protein coupled receptors, via modified turnover of extracellularly active small peptides. (Cancer Sci 2006; 97: 611–617)

Cell-surface proteolytic enzymes regulate cell growth by cleaving and inactivating regulatory small peptides and peptide hormones in normal cells.1 Neutral endopeptidase 24.11 (CD10, enkephalinase, nephrilysin, CALLA, EC 3.4.24.11, metallomembrane endopeptidase) is a type II transmembrane zinc-containing endopeptidase expressed normally in numerous tissues. The enzyme cleaves peptide bonds on the amino side of hydrophobic amino acids and inactivates a variety of physiologically active peptides, including atrial natriuretic factor, substance P, bradykinin, oxytocin, Leu- and Met-enkephalines, neurotensin, bombesin, endothelin-1 and bombesin-like peptides. Loss or decreases in NEP expression have been reported in a variety of malignancies, such as lung,2,3 endometrial,4 prostate,5 and renal cell6 cancers. The roles of NEP in regulation of cell proliferation and other functions have also been investigated in various types of cells.7-11 Overexpression of NEP in mutant Jerkat T cells that failed to express NEP resulted in restoration of PMA-induced growth arrest.12 Inhibition of cell proliferation was observed in androgen-independent prostate cancer cells transfected with NEP.13 Cervical carcinoma cells overexpressing NEP revealed reduced cell proliferation accompanied by a decreased concentration of endothelin-1 in the conditioned medium.5 Reduced NEP may promote peptide-mediated proliferation by allowing accumulation of higher peptide concentrations at the cell surface, and facilitate the development or progression of neoplasia.14 Possible causes include a change in methylation status. Hypermethylation of promoter-associated CpG islands is an important mechanism for inactivation of tumor-suppressor genes in carcinogenesis,13,14 and promoter hypermethylation of NEP has been reported for androgen-independent prostate cancers15,16 and for adult acute lymphocytic leukemia.17 In these malignancies, hypermethylation of CpG dinucleotides in the promoter region of the NEP gene has thus been associated with reduced expression.

Hepatocellular carcinoma remains one of the most common malignancies in the world. Hepatocarcinogenesis is a multistep process involving a variety of genetic and epigenetic alterations.18 In a rat model induced by a CDAA diet in males of the Fischer 344 and Wistar strains, HCC develops on a background of liver cirrhosis, similar to the human case.19 Several molecular abnormalities have been described for HCC induced by a CDAA diet.20,21 We have recently carried out an oligonucleotide microarray analysis using rat liver HCC induced by a CDAA diet,22 which indicated that NEP expression in normal liver was 3.1 times higher than that in HCC (see http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1946). In human HCC, reduced expression has also been reported,22 along with increased expression of endothelin-1, a substrate of NEP.23-25 On the other hand, increased expression of NEP in HCC tissues has been correlated with longer survival.26 These findings may suggest its possible inhibitory effects on liver cell proliferation. So far, however, no mutations in the human NEP gene have been observed in HCC. Frequencies of allelic or regional losses involving the NEP gene,

© 2006 Japanese Cancer Association

doi: 10.1111/j.1349-7006.2006.00227.x

Cancer Sci | July 2006 | vol. 97 | no. 7 | 611–617
located in 3q21-q27, are not particularly high compared to other regions.\(^{(18)}\) These observations may suggest that epigenetic mechanisms could be important in the regulation of NEP expression. In the present study we therefore concentrated attention on the methylation status of the CpG island in the promoter region of the rat \(NEP\) gene in HCC induced with a CDAA diet and rat liver cell lines by MSP, COBRA, and bisulfite genomic sequencing.

Materials and Methods

Ethical considerations

The experimental protocols were approved by the Animal Experimentation Committee of the Sasaki Institute (Tokyo, Japan) prior to their execution under monitoring by the Committee in accordance with the National Institutes of Health Guideline for the Care and Use of Laboratory Animals, the Japanese Government Animal Protection and Management Law Number 105, and the Japanese Government Notification on Feeding and Safekeeping of Animals Number 6.

Animals, diets and animal treatment

Male Fischer 344 rats (5 weeks old) were purchased from Charles River Japan (Kanagawa, Japan) and housed in plastic cages with white flake bedding in an air-conditioned room (25 ± 3°C, 55 ± 8% relative humidity, 10–12 times/h ventilation and 12:12 h L:D cycle). They were used for the experimentation after a 1-week acclimation on basal diet (CRF-1; Oriental Yeast Corporation, Itabashi, Tokyo) and allowed free access to food and tap water throughout the experimentation after a 1-week acclimation on basal diet (CRF-1; Oriental Yeast Corporation, Itabashi, Tokyo) and allowed free access to food and tap water throughout the acclimation and experimental periods. Bodyweight, food consumption and water intake were monitored weekly.

After acclimation, rats were allocated randomly to receive either basal diet or CDAA diet (Dyets, Bethlehem, PA, USA). Five rats on the basal diet and 12 rats on the CDAA diet were killed at 70 weeks after diet initiation. The livers were taken and examined macroscopically. Portions of the macroscopic tumors and background tissue were fixed in 10% neutrally buffered formalin for 24 h, embedded in paraffin, processed and examined histologically. Portions of the macroscopic tumors and background tissue were fixed in 10% neutrally buffered formalin for 24 h, embedded in paraffin, processed and examined histologically. Remaining portions were frozen immediately in liquid nitrogen and stored at −80°C.

Cell culture

RLC-16 is an epithelial cell line from rat liver\(^{(27)}\) and RLC-27 is a liver-derived cell line, which is tumorigenic in nude mice. Both cell lines were purchased from Riken Bioresource Center Cell Bank (Tsukuba, Ibaraki) and cultured in Dulbecco’s Modified Eagle Medium (Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum in collagen-coated Petri dishes at 37°C in a humidified 5% \(\text{CO}_2\) atmosphere.

Genomic DNA and total RNA extraction

Genomic DNA was isolated from liver and liver cell lines using DNeasy Tissue Kit (QIAGEN, Hilden, Germany) and its quality checked by measurement of OD\(_{260}\) and OD\(_{280}\) and 1% agarose gel electrophoresis with ethidium bromide staining. Total RNA was isolated using an RNeasy Midi kit (QIAGEN) and its integrity confirmed by electrophoresis on 1% agarose–formaldehyde gels.

Bisulfite modification

DNA (1 \(\mu\)g) was digested with restriction endonuclease \(\text{HindIII}\) (Promega, Madison, WI, USA), followed by phenol, phenol/chloroform and chloroform extractions, and subsequent ethanol precipitation. After purification, the DNA was denatured in a volume of 20 \(\mu\)L NaOH (final concentration 0.3 M) for 15 min at 37°C. After denaturation, 8.4 \(\mu\)L of 10 mM hydroquinone (Sigma, St Louis, MO, USA) and 120 \(\mu\)L of 3.6 M sodium hydrosulfite (Sigma) at pH 5, both prepared freshly, were added and, after mixing, the samples were incubated in a thermal cycler with 15 cycles of 30 s at 50°C and 15 min at 50°C. Modified DNA was purified using the Wizard DNA purification resin (Promega) according to the manufacturer’s protocol and eluted into 50 \(\mu\)L of water.

Modification was completed with NaOH (final concentration 0.3 M) treatment for 5 min at room temperature, followed by ethanol precipitation. DNA was suspended in TE buffer and used immediately or stored at −20°C. Normal rat liver DNA treated with the CpG methylase, M. \(\text{SssI}\) (New England Biolabs, Beverly, MA, USA) and rat testis DNA were used as methylated and unmethylated DNA controls, respectively (data not shown). The methylation status of these controls was confirmed by bisulfite genomic sequencing.

MSP analysis

Two sets of primers were used to amplify the region of interest: 5NEP-U and 3NEP-U recognize a sequence in which CpG sites are unmethylated (modified by UpG by the bisulfite treatment), and 5NEP-M and 3NEP-M recognize a sequence in which CpG sites are methylated (unmodified by the bisulfite treatment). Each set of primers was designed to examine the methylation status of five CpG sites within the CpG island in the second promoter of the \(NEP\) gene (designated 1, 2 and 20–22; Fig. 1; Table 1). The cycling conditions were 2 min at 94°C, followed by 35 cycles of 94°C for 1 min, 65°C for 1 min and 72°C for 1 min, with final extension elongated to 7 min, for both reactions. The products were visualized on 10% non-denaturing polyacrylamide gels with ethidium bromide.

COBRA assay

Using 3 \(\mu\)L of sodium bisulfite-treated DNA, PCR was carried out using a hot start in a 50-\(\mu\)L reaction with primers 5NEP-1 and 3NEP-1 (Table 1). The cycling conditions were 2 min at 94°C, followed by 15 cycles of 94°C for 1 min, 60°C for 1 min and 68°C for 1 min, with final extension elongated to 7 min.

One microliter of the PCR product was used for the following nested reaction using a hot start with primers 5NEP-2 and 3NEP-2 (Fig. 1; Table 1), which gives a 197-bp main product. The cycling conditions were 2 min at 94°C, followed by 25 cycles of 94°C for 1 min, 68°C for 1 min and 74°C for 1 min, with final extension elongated to 30 min. After amplification, PCR products were digested with restriction endonuclease \(Hinfl\) (Promega) that digests alleles methylated before bisulfite treatment at 37°C for 4 h, and separated on 10% non-denaturing polyacrylamide gels with ethidium bromide staining. This assay was designed to examine the methylation status of two CpG sites in the CpG island (designated 14 and 36; Fig. 1; Table 1). The proportion of methylated versus unmethylated products (digested vs undigested) was quantitated by densitometry using NIH
Bisulfite genomic sequencing of individual alleles

A 197-bp DNA fragment was amplified by PCR as described above. The products included 25 CpG sites in the second promoter of the rat NEP gene (designated 12–36; Fig. 1). 

PCR products were cloned into the TA vector pCR2.1-TOPO (Invitrogen) and transformed into bacteria. Plasmid DNA from isolated clones was purified using the Plasmid Midi kit (QIAGEN) and analyzed by automated DNA sequencing. Complete conversion of cytosines not flanked by guanine was confirmed.

Expression of NEP in liver tissues and cell lines

Reverse transcription was carried out on 3 µg of total RNA using a First-Strand cDNA Synthesis kit (Amersham Biosciences, Uppsala, Sweden) and oligo(dT)18 primer according to the manufacturer’s protocol in a total volume of 50 µL. The primers used were 5′-AGAGGAGGAGAAGCGTGAAT-3′ (sense) and 5′-CTTAACTATCTAC-TTGAC-3′ (antisense) and the cycling conditions were 2 min at 94°C, followed by 23 cycles of 94°C for 1 min, 55°C for 30 s and 72°C for 30 s, which amplified a 460-bp product. PCR products were separated on 2% agarose gels, visualized with ethidium bromide staining, and subsequently underwent densitometry. The values obtained were then normalized to those for β-actin.

Re-expression of NEP by 5-aza-2′-deoxycytidine treatment

Rat cultured cells (5 × 10⁵ cells) were grown for 4 days in the presence of 10 µM of 5-Aza-2′-deoxycytidine (Fluka, St Louis, MO, USA), then harvested for isolation of total RNA and performance of semiquantitative RT-PCR as described above.

Statistical analyses

The statistical significance of differences of means between two groups was assessed using the unpaired Student’s t-test. A value of P < 0.05 was considered to be statistically significant.

Table 1. Primer sequences designed to examine the methylation status of CpG sites within the CpG island in the second promoter of the NEP gene

<table>
<thead>
<tr>
<th>Method</th>
<th>Name</th>
<th>Sequence (5′→3′)</th>
<th>Primer position†</th>
<th>Product size (bp)</th>
<th>Annealing temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisulfite sequencing</td>
<td>5NEP-M</td>
<td>TTGGTTGGGTTATTTGGTC</td>
<td>−409</td>
<td>219</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>3NEP-M</td>
<td>GACCTATCTTACCCGTAGT</td>
<td>−191</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5NEP-U</td>
<td>TTATTGGTTGTATTTTCGGT</td>
<td>−413</td>
<td>223</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>3NEP-U</td>
<td>AACCTATCTTACCCGTAGT</td>
<td>−191</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5NEP-1</td>
<td>GGGTATTAGGTTTTTGGG</td>
<td>−287</td>
<td>197</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>3NEP-1</td>
<td>CCTCCCAACTTCTCAATC</td>
<td>−91</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5NEP-2</td>
<td>GGGTATTAGGTTTTTGGG</td>
<td>−287</td>
<td>197</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>3NEP-2</td>
<td>CCTCCCAACTTCTCAATC</td>
<td>−91</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†Relative to exon 2 transcription start.
Results

Histological findings
All rats survived until their scheduled killing in relatively healthy conditions. Control rats fed a basal diet showed no particular pathological changes. All of the livers from rats fed the CDA diet were macroscopically yellowish-white and appeared cirrhotic with one to three dark-colored large tumoral nodules. Tumors were diagnosed histologically as relatively well-differentiated HCC. The surrounding, non-cancerous areas were cirrhotic, featuring frequent hepatocellular apoptosis and nuclear divisions of hepatocytes. These findings were largely in accordance with our previous reports.

Methylation status of the NEP promoter in HCC, surrounding liver, non-cancerous liver, normal liver and rat liver cell lines
Two separate regulatory regions have been shown for the NEP gene, and sequence analysis of the rat NEP promoter has identified a CpG island in the second promoter region located between exons 1 and 2, as defined by the criteria of Gardiner-Garden and Frommer (G + C content > 50% and observed/expected CpG dinucleotide ratio > 0.6). The CpG island is a 453-bp segment, ranging from −537 to −85 relative to the exon 2 transcription start (Fig. 1). We first evaluated the methylation status of the CpG island by MSP using unmethylated and methylated primer sets (Fig. 2a). The DNA from age-matched normal rats (e.g. N1-N3) demonstrated negative methylation patterns in the region tested, whereas HCC samples exhibited various methylation patterns from negative (e.g. T8) to relatively heavy (e.g. T9) methylation. The two rat liver cell lines RLC-16 and RLC-27 showed a complete methylation pattern. Because the degree of methylation evaluated by MSP differed extensively among HCC samples, a more quantitative method was needed, and therefore we also carried out COBRA (Fig. 2b). In this analysis, DNA amplified by PCR was treated with HinfI, which cleaved CpG that were methylated before bisulfite treatment. CpG sites in HCC exhibited positive digestion of the PCR products (e.g. T1, T3, T7 and T9) or negative results (e.g. T8). When a threshold of ≥15% was used to define a sample as methylated, 75% (nine out of 12 samples) of HCC samples were methylated, whereas none of the normal liver samples (five samples) were methylated.

We next examined the methylation status of a DNA segment containing 25 CpG sites (designated 12–36; Fig. 1) in the CpG island using bisulfite genomic sequencing for normal liver tissue (N1), HCC samples (T3, T7 and T9) and a liver cell line (RLC-27). Eight clones were analyzed for each sample. As shown in Fig. 2c, in the normal liver CpG sites were almost completely unmethylated, whereas in the HCC samples examined they were partially methylated. From the results of sequencing, we have presumed that positive bands detected with unmethylated MSP primers in HCC may be largely due to partially methylated alleles in tumor cells, but the possibility of contamination of surrounding non-cancerous tissues could not be excluded. Complete methylation of CpG sites within the region tested was detected in the RLC-27 case.

Methylation status was also investigated by MSP in three surrounding, non-cancerous liver samples and they gave strong unmethylated bands (Fig. 2d). However, in two of these samples (NC3 and NC9), methylated bands were also detected, although the extent of methylation appeared weaker than in HCC themselves (T3 and T9, respectively, Fig. 2a).

Expression of NEP in HCC, normal liver and rat liver cell lines
Previous studies have shown aberrant methylation of the CpG island located in the second promoter region to be a
cell lines RLC-16 and RLC-27 were treated with 5-aza-2'-deoxycytidine at 10 μM for 4 days. The promoter of these cell lines was heavily methylated (Fig. 2a,b) and the mRNA expression of NEP was negative under basal conditions, but gene expression at the mRNA level was restored in both cell lines after treatment (Fig. 4).

Discussion

The present study provides clear evidence that methylation of CpG dinucleotides in the promoter region of NEP is a common event in a rat HCC model. Furthermore, on quantitation of the extent of methylation in HCC samples, an inverse correlation with mRNA expression of NEP was observed and in vitro studies demonstrated that exposure of cultured rat liver cell lines with complete promoter methylation to 5-aza-2'-deoxycytidine restored mRNA expression. The results also indicated that methylation of the NEP gene is not an effect of aging, because age-matched normal livers were almost completely unmethylated. In HCC samples that showed positive methylation patterns, their surrounding, non-cancerous, cirrhotic areas also gave weak methylation patterns, indicating that methylation of the NEP gene is a progressive change, caused by administration of the CDAA diet. In the current study, nine out of 12 HCC samples were methylated (75%) and therefore, the frequency of methylation seems higher than in patients with hormone-naïve prostate cancer (three out of 21 patients, 14%) or adult acute lymphocytic leukemia (eight out of 80 patients, 10%).(17) Promoter methylation has also been reported for several tumor-suppressor genes in human HCC. The most frequently methylated genes include SOCS-1, GSTP, APC, E-cadherin and p15.(30–32) One study indicated that the SOCS-1, GSTP and APC genes were methylated in 65%, 54% and 53% of patients with HCC, respectively,(33) so it appears that in rat HCC the NEP gene may be methylated with similarly high frequency. In HCC, expression of two crucial methyltransferases, DNMT1 and DNMT3a, was shown to be elevated compared to non-cancerous liver,(34) suggesting that epigenetic mechanisms may be important. It is thus important to detect genes regulated by methylation of the promoter region during HCC development.

Hypermethylation of the NEP promoter and reduced expression has been observed in androgen-independent prostate cells, but not in androgen-sensitive cells,(15) and it has been suggested that androgen withdrawal triggers silencing of the NEP gene in prostate cancers.(5) Androgen withdrawal is the primary therapy for patients who develop locally advanced or metastatic prostate cancer. Although responses to androgen withdrawal occur in the majority of people with the disease, treatment failure and tumor growth develop within 2 years. Long-term use of oral contraceptives and androgenic steroids can induce benign and malignant hepato-cellular tumors.(35) In addition, HCC is more prevalent in men than in women, and the CDAA diet used in the current study induces HCC in male rats. These findings have suggested the possibility that androgen is involved in its pathogenesis,(36) and at least portions of human HCC are considered to be androgen-dependent.(37–39) As in prostate cancer, anti-androgen therapy for unresectable human HCC has been tried, but did not prove effective at prolonging survival when tested in
a randomized controlled trial. The mechanisms of these observations are still obscure, but they suggest that HCC may use alternative sources to stimulate cell proliferation. Involvement of sex hormones and their receptors as a mechanism that may trigger inactivation of NEP need to be investigated in the future. Several lines of evidence support the involvement of biologically active small peptides and their receptors in hepatocarcinogenesis. In human HCC, altered expression of endothelin-1, a substrate of NEP, is observed. Neurotensin is another substrate of NEP, which stimulates the growth of hepatocytes. Aberrant expression of regulatory peptide receptors, such as somatostatin, vasoactive intestinal peptide, endothelin B, and substance P receptors, all of which are members of the GPCR superfamily, has also been reported. Although the contribution of cell-surface peptidases, including NEP, to the regulation of bioactive small peptides in the liver remains to be elucidated, reduced expression of NEP has been observed in HCC. Moreover, elevated expression of NEP in HCC explored by immunohistochemistry has been correlated with longer survival. These may suggest its possible roles in HCC progression. As cell-surface peptidases modulate the activity of peptide factors and regulate access to adjacent cells, their loss of function may result in an inability to inactivate stimulatory peptides. Whereas loss or decreased expression of NEP has been observed in various malignancies, the lack of tools to simply evaluate concordant changes of regulatory molecules in these processes has hitherto made investigation of the underlying mechanisms difficult. Recently developed technologies such as microarray systems may facilitate studies in this direction.

In the above-mentioned oligonucleotide microarray analysis using rat liver HCC induced by the CDAA diet, we detected 146 differentially expressed genes, which were classified into four clusters solely based on their expression patterns. Genes belonging to the categories cytokines and cell receptors were both enriched in a cluster characterized by reduced mRNA in HCC compared with age-matched normal liver (P < 0.05, Fisher’s exact test). The GPCR in this cluster included opioid receptor x1, somatostatin receptor 1, endothelin receptor A and endothelin receptor B. The study thus elucidated concordant changes in expression of certain small peptides and cell receptors during hepatocarcinogenesis. The causes of the altered expression are largely unknown, but based on expression of bioactive peptides and receptors detected with the microarrays, we hypothesize that a negative feedback mechanism triggered by loss or reduced expression of cell-surface peptidases could be involved. In the HCC, peptidase expression is attenuated, and cells may not be able to inactivate bioactive peptides. The signals initiated by binding of the ligands to receptors stimulate cell growth. Excessive signaling may in turn trigger a negative feedback system, resulting in a suppression of transcription of peptides and receptors in HCC.

In summary, we here detected a high incidence of aberrant methylation of the promoter of the NEP gene in rat HCC, resulting in its reduced expression in cancer cells. We propose that altered expression of NEP may be a factor that can cause concordant changes in signal-transducing molecules during the development of HCC in the CDAA rat model. Because of the high incidence of promoter methylation and reduced expression of the NEP gene, this model should find application for further exploration of the involvement of cell-surface peptidases in carcinogenesis.

Acknowledgments

We thank Dr. Yoshiyuki Hashimoto (Kyoritsu University of Pharmacy) for constant advice, and Ms Hiromi Asako and Ms Chihami Kajiwara (Department of Pathology, Sasaki Institute) for expert technical assistance. This work was supported by a Research Grant of the Princess Takamatsu Cancer Research Fund of Japan (01-23308).

References

26 Mondada D, Bosman FT, Fontolliet C, Seelentag WK. Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival. *Virchows Arch* 2006; 448: 35–45.